Tags

Type your tag names separated by a space and hit enter

The gastrointestinal pharmacology of cannabinoids.
Curr Opin Pharmacol. 2001 Dec; 1(6):597-603.CO

Abstract

The digestive tract contains endogenous cannabinoids (anandamide and 2-arachidonylglycerol) and cannabinoid CB1 receptors can be found on myenteric and submucosal nerves. Activation of CB1 receptors inhibits gastrointestinal motility, intestinal secretion and gastric acid secretion. The enteric location of CB1 receptors could provide new strategies for the management of gut disorders.

Authors+Show Affiliations

Department of Experimental Pharmacology, University of Naples Federico II, Italy. aaizzo@unina.itNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

11757815

Citation

Izzo, A A., et al. "The Gastrointestinal Pharmacology of Cannabinoids." Current Opinion in Pharmacology, vol. 1, no. 6, 2001, pp. 597-603.
Izzo AA, Mascolo N, Capasso F. The gastrointestinal pharmacology of cannabinoids. Curr Opin Pharmacol. 2001;1(6):597-603.
Izzo, A. A., Mascolo, N., & Capasso, F. (2001). The gastrointestinal pharmacology of cannabinoids. Current Opinion in Pharmacology, 1(6), 597-603.
Izzo AA, Mascolo N, Capasso F. The Gastrointestinal Pharmacology of Cannabinoids. Curr Opin Pharmacol. 2001;1(6):597-603. PubMed PMID: 11757815.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The gastrointestinal pharmacology of cannabinoids. AU - Izzo,A A, AU - Mascolo,N, AU - Capasso,F, PY - 2002/1/5/pubmed PY - 2002/3/2/medline PY - 2002/1/5/entrez SP - 597 EP - 603 JF - Current opinion in pharmacology JO - Curr Opin Pharmacol VL - 1 IS - 6 N2 - The digestive tract contains endogenous cannabinoids (anandamide and 2-arachidonylglycerol) and cannabinoid CB1 receptors can be found on myenteric and submucosal nerves. Activation of CB1 receptors inhibits gastrointestinal motility, intestinal secretion and gastric acid secretion. The enteric location of CB1 receptors could provide new strategies for the management of gut disorders. SN - 1471-4892 UR - https://www.unboundmedicine.com/medline/citation/11757815/The_gastrointestinal_pharmacology_of_cannabinoids_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1471-4892(01)00102-3 DB - PRIME DP - Unbound Medicine ER -